Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager – based Immunotherapeutics for Multiple Cancer Targets
Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.
Affimed will apply its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which enables the generation of both NK cell and T cell-engaging antibodies, to discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech. The collaboration includes candidate products generated from Affimed’s ROCK® platform and multiple undisclosed solid and hematologic tumor targets.
Affimed and Genentech will collaborate on the discovery, early research and late-stage research phases. Genentech will be responsible for clinical development and commercialization worldwide. “We are incredibly excited to work with Genentech, a leader in oncology with a long history of excellence in the discovery and development of medicines to treat cancer,” said Dr. Adi Hoess, Affimed’s CEO. “This strategic partnership marks an important step on our path to leverage the full potential of innate immune cells in oncology.”
Original Press Release.